Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00040872

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

Phase 3

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 350

Registration Number: NCT00047138

Locations: 🇩🇪
Universitaetsklinikum des Saarlandes, Homburg, Germany
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands

and more 1 locations

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Phase 3

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: doxorubicin hydrochloride
Drug: busulfan
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: conventional surgery
Drug: melphalan
Radiation: radiation therapy
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 1200

Registration Number: NCT00020566

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸
West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States

and more 100 locations

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Doxorubicin hydrochloride
Drug: Estramustine Phosphate Sodium
Drug: Flutamide
Drug: Nilutamide
Drug: Ketoconazole
Procedure: Conventional Surgery
Drug: Therapeutic Hydrocortisone
Drug: Vinblastine

First Posted Date: 2003-01-27

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 306

Registration Number: NCT00002855

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

Phase 2

Terminated

Conditions: Cardiac Toxicity
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-06-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00019864

Locations: 🇺🇸
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States

and more 1 locations

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Phase 2

Completed

Conditions: Adrenocortical Carcinoma
Brain and Central Nervous System Tumors
Head and Neck Cancer
Liver Cancer
Malignant Mesothelioma
Pheochromocytoma
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-10

Lead Sponsor: Ottawa Regional Cancer Centre

Target Recruit Count: 30

Registration Number: NCT00002608

Locations: 🇨🇦
Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus, Ottawa, Ontario, Canada

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer

Interventions: Drug: thalidomide
Drug: doxorubicin hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00006016

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00052351

Locations: 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Phase 3

Completed

Conditions: Childhood Mixed Cellularity Classical Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma
Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Cytarabine
Biological: Filgrastim
Drug: Dexamethasone
Radiation: Involved-Field Radiation Therapy
Drug: Prednisone
Drug: Vincristine Sulfate Liposome

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-12

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1734

Registration Number: NCT00025259

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 172 locations

Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Phase 3

Completed

Conditions: Ovarian Cancer
Kidney Cancer
Pheochromocytoma
Endometrial Cancer
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2014-08-08

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 350

Registration Number: NCT00002641

Locations: 🇦🇹
Karl-Franzens-University Graz, Graz, Austria
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 42 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy